Claims:

1. A method of detecting breast cancer or lung cancer in a patient comprising the steps of:

a) Measuring an amount of a polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y192 in a first cell sample isolated from the patient; and

b) Comparing the amount of polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y192 in the cell sample to an amount of polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y192 in a second cell sample isolated from normal, non-cancerous cells,

wherein an amplified amount of polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y192 in the first cell sample relative to the amount of polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y192 in the second cell sample indicates breast cancer or lung cancer is present in the first cell sample.

2. The method of claim 1 further comprising measuring the amount of the polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y231 in the first and second cell sample wherein an amplified amount of polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y192 and Y231 in the first cell sample relative to the amount of polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y192 and Y231 in the second cell sample indicates cancer is present in the first cell sample.

3. The method of claim 1 or 2 whereby the cancer is dependent on EGFR, c-Src, c-Yes, ER, Wnt, WBP2 or E2F.

4. The method of any one of claims 1 to 3 whereby the amount of the polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine is measured with an isolated phosphorylation site-specific antibody that specifically binds to a WW-domain binding protein of SEQ ID. NO. 1 only when the polypeptide is phosphorylated at the tyrosine Y192 or the tyrosine Y192 and the tyrosine Y231 wherein the antibody does not bind the polypeptide of SEQ ID No. 1 when it is not phosphorylated at said tyrosine.

5. The method of any one of claims 1 to 3 further comprising the steps of:

c) bringing the polypeptide of SEQ ID No. 1 into contact with a polynucleotide probe or primer comprising a polynucleotide sequence capable of hybridising selectively to the polypeptide of SEQ ID No. 1 only when the polypeptide is phosphorylated at the tyrosine Y192 or the tyrosine Y192 and the tyrosine Y231 under suitable hybridising conditions; and

d) detecting any duplex formed between the probe or primer and the polypeptide of SEQ ID No. 1 phosphorylated at said tyrosine.

6. The method of any one of claims 1 to 3 whereby the amount of the polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine is measured with an isolated phosphorylation site-specific aptamers that specifically binds to a WW-domain binding protein of SEQ ID. NO. 1 only when the polypeptide is phosphorylated at the tyrosine Y192 or Y231 or the tyrosine Y192 and the tyrosine Y231 wherein the aptamers does not bind the polypeptide of SEQ ID No. 1 when it is not phosphorylated at said tyrosine.

7. The method of any one of claims 1 to 6 whereby the first and second cell sample are isolated from a nuclear fraction of the cell.

8. An agent capable of interfering with phosphorylation of tyrosine Y192 and Y231 in the polypeptide of SEQ ID NO. 1, wherein the agent is a vector that overexpresses a fragment of polypeptide of SEQ ID No. 1 including tyrosine sites Y192 and Y231 and a nuclear localization signal.

9. An agent comprising a vector that overexpresses a phosphorylation-defective polypeptide of SEQ ID. NO. 1 that includes a mutation at the tyrosine Y192 and Y231.

10. The agent of claim 9 wherein the phosphorylation-defective peptide comprises SEQ ID. NO. 5; or SEQ ID. NO. 6.


11. The agent of claim 9 or 10 wherein said phosphorylation-defective polypeptide of SEQ ID. NO. 1 includes a mutation of the tyrosine Y192 and Y231 to phenylalanine.

12. A cell line producing an agent of any one of claims 8 to 11.

13. The agent of claim 11 further comprising a TCF/β-catenin inhibitor, anti-EGFR, anti-src, anti-c-Yes, anti-E2F, or anti-ERα compounds.

14. A composition comprising the agent of claim 11 and a TCF/β-catenin inhibitor or an anti-estrogen receptor α compound.

15. The agent of claim 13 or the composition of claim 14 wherein the TCF/β-catenin inhibitor is an FH535 of formula 1



16. The agent of claim 13 or the composition of claim 14 wherein the anti-estrogen receptor α compound is a Fulvestrant of formula 2

